MBS-309

N/A

Report date: 2024/07/03 18:05:47

Base Information

Drug NameMBS-309
Drug Alias NameMBS-309
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 antagonistsInterleukin-2 replacements
TargetsInterleukin-2Programmed cell death protein 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A